Jilin Changlong Pharmaceutical released its annual performance, with a net profit attributable to shareholders of 148 million yuan, a year-on-year decrease of 23.43%
I'm PortAI, I can summarize articles.
According to the news from Zhitong Finance APP, Jilin Changlong Pharmaceutical released its annual performance for the year ending December 31, 2023. The group achieved revenue of RMB 842 million, unchanged year-on-year; the attributable net profit to owners of the company was RMB 148 million, a decrease of 23.43% year-on-year; earnings per share were 26.45 cents
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments